We argue that in constellations of high OTUD6B expression in MM patients, inhibition of the proteasome likely further augments LIN28B expression to alleviate the efficacy of bortezomib thus possibly explaining the adverse outcome of these patients. Here, OTUD6B is linked to Miyoshi myopathy.